Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug

Published 10/07/2025, 13:50
© Reuters.

Investing.com -- Cognition Therapeutics Inc (NASDAQ:CGTX) stock surged 75% following the company’s end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its Alzheimer’s disease treatment candidate.

The clinical-stage neurodegenerative disease drug developer met with FDA officials on July 9 to review results from the Phase 2 study of its drug zervimesine (CT1812) and discuss plans for a Phase 3 program that would support a new drug application.

"We discussed the results from the Phase 2 ’SHINE’ Study in Alzheimer’s disease and our proposed Phase 3 plan with the FDA and believe we have a path forward for the development of zervimesine in the treatment of Alzheimer’s disease," said Lisa Ricciardi, president and CEO of Cognition.

The company expects to receive formal minutes from the FDA in August to confirm its development pathway for the potential Alzheimer’s treatment.

Investors reacted enthusiastically to the news of potential regulatory progress for zervimesine, which is being developed to treat neurodegenerative disorders. The significant stock movement reflects market optimism about the drug’s development timeline following the regulatory meeting.

Cognition Therapeutics is focused on advancing treatments for conditions affecting cognitive function, with Alzheimer’s disease representing a substantial market opportunity given the limited treatment options currently available for the progressive neurological disorder.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.